1-3 of 3
Annelise Segers
Close
Sort by
Journal Articles

A Randomized, Open-Label, Blinded Outcome Assessment Trial Evaluating the Efficacy and Safety of LMWH/Edoxaban Versus Dalteparin for Venous Thromboembolism Associated with Cancer: Hokusai VTE-Cancer Study

Gary E. Raskob, PhD, Nick Van Es, MD, Peter Verhamme, MD PhD, Marc Carrier, MD, Marcello Di Nisio, MD, David A. Garcia, MD, Michael A. Grosso, MD, Ajay K. Kakkar, MBBS, Michael J. Kovacs, MD, Michele F. Mercuri, MD PhD FAHA, Guy Meyer, MD, Annelise Segers, MD, Minggao Shi, PhD, Tzu-Fei Wang, MD, Erik Yeo, MD FACP, FRCPC, George Zhang, PhD, Jeffrey I. Zwicker, MD, Jeffrey I. Weitz, MD, Harry R. Büller, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): LBA-6.
https://doi.org/10.1182/blood.V130.Suppl_1.LBA-6.LBA-6
Published: 2017
Journal Articles

Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis

Harry Roger Buller, MD PhD, Claudette Bethune, PhD, Sanjay Bhanot, MDPhD, David Gailani, MD, Brett P. Monia, PhD, Gary E. Raskob, PhD, Annelise Segers, Peter Verhamme, MD PhD, Jeffrey I. Weitz, MDFRCPC
Journal: Blood
Blood (2014) 124 (21): LBA-1.
https://doi.org/10.1182/blood.V124.21.LBA-1.LBA-1
Published: 2014
Journal Articles

A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein–DVT Dose-Ranging Study

Clinical Trials & Observations
Harry R. Buller, Anthonie W. A. Lensing, Martin H. Prins, Giancarlo Agnelli, Alexander Cohen, Alexander S. Gallus, Frank Misselwitz, Gary Raskob, Sebastian Schellong, Annelise Segers
Journal: Blood
Blood (2008) 112 (6): 2242–2247.
https://doi.org/10.1182/blood-2008-05-160143
Published: 2008
Includes: Supplemental data